Hot Defensive Companies For 2015

Sergei Fedorov is generally regarded as the greatest defensive forward in the history of the National Hockey League.  He led the Detroit Red Wings to Stanley Cup championships in 1997, 1998, and 2002, and won a Hart Trophy as the league�� most valuable player in 1994.

But like many high-profile athletes, it appears that Fedorov has been the victim of an unscrupulous financial advisor.  In 2009, Fedorov sued financial advisor Joseph P. Zada, of Grosse Pointe, Michigan.   Zada did not answer the Complaint, and the Wayne County Circuit Court entered a default judgment exceeding $60 million in Fedorov�� favor against Zada.   Court records evince vigorous effort to collect the judgment in the four years since it was entered.  According to the Detroit Free Press nothing has been collected on it.

$60 million represents Fedorov�� annual player�� salary at the height of his playing career, $10 million, for six years.  Fedorov is 43 years of age and retired as a player.  It is unlikely that he will make the kind of money in his post-playing career that he did as a player.  That train has passed.

Hot Defensive Companies For 2015: Special Opportunities Fund Inc.(SPE)

Special Opportunities Fund, Inc. is a close-ended fund of funds launched and managed by Brooklyn Capital Management LLC. It invests in close-ended funds investing in public equity and fixed income markets. The fund employs a combination of value, opportunistic and special situations strategies to make its investments. It benchmarks the performance of its portfolio against the S&P 500 Index. The fund was previously known as Insured Municipal Income Fund, Inc. Special Opportunities Fund, Inc. was formed on February 18, 1993 and is domiciled in the United States.

Advisors' Opinion:

• [By Whopper Investments]

  For example, his Special Opportunity Fund (SPE) needed more capital to effectively implement its activist strategy after he took over. Unfortunately, most of the ways to raise capital are expensive and seriously dilute shareholder value. For example, a common stock offering, the most common way a closed end fund would raise capital, has to be priced at a discount and an investment bank needs to be paid to organize and sell it. Obviously, paying to issue shares at a discount is a disaster for long term shareholder value, so he instead pursued a rights offering for convertible preferred stock, which allowed the company to raise money without the expense of an investment bank while allowing shareholders the opportunity to increase their holdings in the fund without paying a commission. From the prospectus,

Hot Defensive Companies For 2015: Pluristem Therapeutics Inc.(PSTI)

Pluristem Therapeutics Inc., a bio-therapeutic company, engages in the research, development, and commercialization of standardized cell therapy products for the treatment of life threatening diseases. The company?s products are derived from human placenta, a non-controversial, non-embryonic, adult cell source. Its Placental adherent stromal cells are grown in the company's proprietary PluriX three-dimensional process that allows cells to grow in a natural environment. The company provides PLX-PAD that has completed Phase I clinical trials for people suffering from peripheral artery disease. It also offers various product candidates for diabetic foot ulcers, adjuvant hip replacement surgery, athletic injuries, inflammatory bowel disease, multiple sclerosis, neuropathic pain, ischemic stroke, adjuvant for UCB transplantation, and radiation exposure. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is headquartered in Haifa, Israel.

Advisors' Opinion:

• [By John Udovich]

  Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector:

Top Industrial Disributor Companies To Watch In Right Now: Genel Energy PLC (GEGYF.PK)

Genel Energy plc, formerly Vallares PLC, is an exploration and production company. It is an independent oil producer in the Kurdistan Region of Iraq. The Group has two reportable business segments, which are its oil and gas exploration and production business in the KRI and its oil and gas exploration business in Africa. The Company had operational bases in Ankara, Turkey; in Taq Taq, Erbil and Suleimaniah in the Kurdistan Region, and in London. The Company�� oil producing fields of Taq Taq (in which it held a 44% interest) and Tawke (25% interest) had estimated gross proven and probable reserves of 1.2 billion barrels of oil and proven, probable and possible reserves of 1.9 billion barrels of oil. The Company�� subsidiaries include: Genel Energy Holding Company Ltd, Genel Energy Somaliland Limited, A&T Petroleum Limited, Genel Energy UK Services Limited, Genel Energy Netherlands Holding 2 B.V. and Genel Energy Somaliland Limited. Advisors' Opinion:

• [By Street Smart Investor]

  DNO International is an independent E&P company, geographically focused on the Middle East and North Africa with operations in Yemen, the Kurdistan region of Iraq, Tunisia, Oman, Ras Al Khaimah and Somaliland. The company's asset portfolio currently stands at 20 assets in six countries. For the year ended December 2012, DNO International has proven and probable reserves of 520.3 MMboe with 90% of the reserves in the Kurdistan region of Iraq. The company's reserves in Kurdistan come from the Tawke oil block, which is among the largest oil blocks in Kurdistan. DNO International has a 55% stake in the Tawke block with Genel Energy PLC (GEGYF.PK) holding a 25% stake. The remaining 20% stake is held by the Kurdistan Regional Government. For the first half of 2013, DNO International had a production rate of 33,917 boepd, which includes production from Kurdistan, Oman and Yemen.

Hot Defensive Companies For 2015: Cleantech Transit Inc (CLNO)

Cleantech Transit, Inc., incorporated on June 28, 2006, is a development-stage company. The Company focuses to explore opportunities in the development and production of hybrid, electric, alternative fuel and diesel heavy duty transit buses, luxury motor coaches and tour buses. On July 11, 2011, the Company formed Cleantech Energy, Inc. as a wholly owned subsidiary. In February 2013, the Company announced that acquired from Crown Equity Holdings Inc., Crown Buy Rite.

On July 25, 2011, the Company formed Cleantech Exploration Corp. as a wholly owned subsidiary. On October 31, 2011, the Company acquired a 40% interest in Ortigalita Power Systems, LLC a waste power generating project in California.

Advisors' Opinion:

• [By CRWE]

  Cleantech Transit, Inc. (OTCMKTS:CLNO) (www.cleantechtransit.net ) through its Discovery Carbon subsidiary, develops emissions offset strategies for companies, municipalities, and countries. Today, CLNO has surged (+5.91%) up +0.013 at $.233 with 60,195 shares in play thus far (ref. google finance Delayed: 1:08PM EDT July 22, 2013), but don�� let this get you down.

  CLNO�� daily range is at ($.245 – $.226) thus far and currently at $.233 would be considered a (+21081.81%) gain above the 52 wk low of $.0011. The stock is up +0.23 ( +10490.91%) since the concerning dates of January 23, 2013 ��July 22, 2013. +10490.91% is the 6 month high and rightly so.

• [By CRWE]

  Cleantech Transit, Inc. (OTCMKTS:CLNO) (www.cleantechtransit.net ) through its Discovery Carbon subsidiary, develops emissions offset strategies for companies, municipalities, and countries. Today, CLNO has�shed (+11.11%) down -0.025 at $.200 with 580,687 shares in play thus far (ref. google finance Delayed: 1:06PM EDT July 17, 2013), but don�� let this get you down.

  CLNO�� daily range is at ($.23 – $.1615) thus far and currently at $.200 would be considered a (+18081.81%) gain above the 52 wk low of $.0011. The stock is up +0.20 ��( +11664.71%) since the concerning dates of January 18, 2013 ��July 17, 2013. +11664.71% is the 6 month high and rightly so.

• [By CRWE]

  Today, CLNO has surged (+0.04%)�0.000 at $.259 with�229,233 shares in play thus far (ref. google finance Delayed: 3:24PM EDT July 9, 2013).

  Cleantech Transit, Inc. (OTCMKTS:CLNO) (www.cleantechtransit.net ) through its Discovery Carbon subsidiary, develops emissions offset strategies for companies, municipalities, and countries. Today, CLNO has surged (+0.04%) 0.000 at $.259 with 229,233 shares in play thus far (ref. google finance Delayed: 3:24PM EDT July 9, 2013). Earlier this morning (July 8), this company hit as low as $.222 and as high as $.265.

  Could it be�because of�CLNO previously announced it plans to change its name to EQCO2, Inc. and also the plan for a 1 for 5 forward stock split for its common stock? (July 5) Cleantech announced that the process for both is underway and is expected to occur before the end of July.

  FYI ��(July 5) Cleantech Transit, Inc. Files SEC form 8-K http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9389837

  FYI ��(July 3) Cleantech Transit, Inc. Files DEF 14C http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9386382

• [By CRWE]

  Cleantech Transit, Inc. (OTCMKTS:CLNO) (www.cleantechtransit.net ) through its Discovery Carbon subsidiary, develops emissions offset strategies for companies, municipalities, and countries. Today, CLNO has surged (+6.19%) up +0.014 at $.240 with 201,039 shares in play thus far (ref. google finance Delayed: 11:47AM EDT July 23, 2013), but don�� let this get you down.

  CLNO�� daily range is at ($.251 – $.226) thus far and currently at $.240 would be considered a (+21718.18%) gain above the 52 wk low of $.0011. The stock is up +0.24 ( +10809.09%) since the concerning dates of January 25, 2013 ��July 22, 2013. +10809.09% is the 6 month high and rightly so.

Hot Defensive Companies For 2015: Conmed Corp (CNMD)

CONMED Corporation (CONMED), incorporated on February 10, 1970, is a medical technology company/ The Company emphasizes on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The Company operates in five segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care.

Arthroscopy

The Company offers a range of devices and products for uses in arthroscopic surgery. The Company's arthroscopy products include powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants as well as related disposable products and fluid management systems. The Company also offers a line of video Endoscopy products suitable for uses in multi-specialty clinical environments beyond orthopedic arthroscopy, including laparoscopy, ear, nose and throat (ENT), gynecology and urology, as well as integrated operating room systems and equipment.

Powered Surgical Instruments

Electric, battery or pneumatic powered surgical instruments are used to perform orthopedic, arthroscopic and other surgical procedures where cutting, drilling or reaming of bone is required. Each power system consists of one or more handpieces and related accessories as well as disposable and limited reusable items (e.g., burs, saw blades, drills and reamers). Powered instruments are categorized as either small bone, large bone or specialty powered instruments. Specialty powered instruments are utilized in procedures such as spinal surgery, neurosurgery, ENT, oral/maxillofacial surgery, and cardiothoracic surgery.

The Company's line of powered instruments is sold principally under the Hall Surgical brand name, for use in large and small bone orthopedic, arthroscopic, oral/maxillofaci! al, podiatric, plastic, ENT, neurological, spinal and cardiothoracic surgeries. Large bone, neurosurgical, spinal and cardiothoracic powered instruments are sold primarily to hospitals while small bone arthroscopic, otolaryngological and oral/maxillofacial powered instruments are sold to hospitals, outpatient facilities and physicians offices.

The Company's powered instruments product line includes the MPower battery system. This orthopedic power system is specifically designed to meet the requirements of orthopedic applications. The MPower battery system allows a facility to purchase a single power system to perform total joint arthroplasty, trauma, arthroscopy, and small bone procedures. The system also provides a multitude of battery technologies to meet the varying needs of hospitals worldwide.

Electrosurgery

The use of electrosurgical units and associated surgical tools is commonplace in the hospital surgical suite, surgery centers, clinics and physician offices. Electrosurgery is routinely used to cut and coagulate tissue and small vessels in open and laparoscopic procedures using energy produced through radio frequency (RF) technology. Electrosurgery can be used in almost all surgical procedures including specialties, such as general, gynecology, orthopedics, cardiology, thoracics, urology, neurology, and dermatology. The Company�� portfolio consist of energy-based products is the Argon Beam Coagulation (ABC) technology. ABC technology combines the use of argon gas and electrosurgical energy to allow the surgeon to produce a surface coagulation which results in less tissue damage.

Patient Care

The Company's patient care product line includes a line of vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, electrocardiogram (ECG) electrodes and cables, cardiac defibrillation and pacing pads and blood pressure cuffs. The Company also offers a line of suction instruments and tubing for use in the! operatin! g room, as well as a line of intravenous (IV) products for use in the critical care areas of the hospital.

Endosurgery

Endosurgery (also referred to as minimally invasive surgery or laparoscopic surgery) is surgery performed without a incision. The Company's Endosurgical products include the Reflex and PermaClip clip appliers for vessel and duct ligation, Universal S/I (suction/irrigation) and Universal Plus laparoscopic instruments and specialized suction/irrigation electrosurgical instrument systems for use in laparoscopic surgery. The Company also offers cutting and dilating trocars, suction/irrigation accessories, laparoscopic scissors, dissectors and graspers, active electrodes, insufflation needles and linear cutters and staplers for use in laparoscopic surgery. The Company's disposable skin staplers are used to close large skin incisions with surgical staples, thus eliminating the time consuming suturing process. CONMED Endosurgery also offers a uterine manipulator called VCARE for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures.

Endoscopic Technologies

The Company offers a line of minimally invasive diagnostic and therapeutic products used in conjunction with procedures, which requires flexible endoscopy. The Company's principal customers include gastrointestinal (GI) endoscopists, pulmonologists, and nurses who perform both diagnostic and therapeutic endoscopic procedures in hospitals and outpatient clinics.

The Company's primary focus is to identify, develop, acquire, manufacture and market differentiated medical devices, which improve outcomes in the diagnosis and treatment of gastrointestinal and pulmonary disorders. The Company's diagnostic and therapeutic product offerings for GI and pulmonology include mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and ! polypecto! my.

The Company competes with Smith & Nephew, plc, Arthrex, Inc., Stryker Corporation, ArthroCare Corporation, Johnson & Johnson: DePuy Mitek, Inc., Biomet, Inc., Medtronic, Inc. Midas Rex and Xomed, Synvasive Technology, Inc., Synthes, Inc., MicroAire Surgical Instruments, LLC, Zimmer Holdings, Inc., Covidien Ltd.; Valleylab, Medline Industries, Inc., ERBE Elektromedizin GmbH, Megadyne, Kendall, 3M Company, Ethicon Endo-Surgery, Inc, U.S.Surgical, Boston Scientific Corporation, Wilson-Cook Medical, Inc, Olympus America, Inc. and STERIS Corporation.

Advisors' Opinion:

• [By Seth Jayson]

  Margins matter. The more CONMED (Nasdaq: CNMD  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong CONMED's competitive position could be.

• [By James Brumley]

  Shares of MDT stock have fallen 6% since their early January peak, but have been in an uptrend since late 2011 … one of the few stocks in the medical device world that has been rock-solid in a rocky environment.

  Medical Devices: ConMed Corp. (CNMD)

  With a market cap of only $1.2 billion, ConMed Corp. (CNMD) isn’t exactly a household name. That doesn’t mean CNMD stock can’t be a potent addiction to a portfolio, though.